CSL names Gordon Naylor chair: 5% profit target tests CSL stock
Published on 10/26/2026 at 09:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLeadership change and recovery test
- Gordon Naylor is due to become CSL chair on March 31, 2027.
- Fiscal 2027 guidance calls for 5 percent underlying profit growth.
- CSL stock trades at EUR 121.40 at 9:04 a.m. CET at Lang & Schwarz on October 26, 2026.
- CSL's annual general meeting is scheduled for October 27, 2026.
CSL (ISIN AU000000CSL8) is preparing another leadership change after Gordon Naylor was named to succeed Brian McNamee as chair on March 31, 2027, according to Boerse Express. The move adds a board transition to the appointment of Deborah Waterhouse as chief executive from February 1, 2027.
Three events reset leadership
CSL's recent sequence points to a company managing both operational and legal pressure. On October 21, 2026, CSL appointed Waterhouse as its next chief executive, effective February 1, 2027, as Business News Today reported. On October 22, 2026, a shareholder class action concerning financial forecasts was disclosed, with CSL denying liability, according to MarketScreener. The chair succession followed on October 25, 2026.
What does 5 percent growth require?
Management expects fiscal 2027 revenue to remain broadly in line with fiscal 2026 at constant currency, while underlying net profit after tax is forecast to grow 5 percent. CSL Behring generated USD 11.387 billion in fiscal 2026 revenue, while CSL Vifor generated USD 2.379 billion and is expected to face a 25 percent revenue decline in fiscal 2027, according to Business News Today. That split makes cost savings and execution central to the recovery case rather than revenue growth alone.
The next dates are already set
CSL's annual general meeting is scheduled for October 27, 2026, according to the company's investor-relations page. The next fiscal 2027 half-year results are scheduled for February 10, 2027, while Waterhouse is due to take over on February 1, 2027, according to MarketScreener.
Stock valuation depends on execution
CSL's equity market value was AUD 94.2 billion on October 23, 2026, when its Australian shares closed at AUD 196.70. In Europe, the stock was trading at EUR 121.40 at Lang & Schwarz on October 26, 2026 at 9:04 a.m. CET. The leadership plan offers clearer accountability, but the next reporting milestones will show whether profit growth is spreading beyond cost reductions and whether the Vifor decline is being contained. The further course of trading is shown by the continuously updated real-time quote of CSL stock.
CSL market and company data
- Company: CSL Limited
- ISIN: AU000000CSL8
- Ticker: CSL
- Primary exchange: ASX
- Price Lang & Schwarz (as of October 26, 2026, 9:04 a.m. CET): EUR 121.40
- Market capitalization: AUD 94.2 billion (as of October 23, 2026)
- Sector / Industry: Pharmaceuticals and biotechnology
- Next earnings date: February 10, 2027
Market context: Market report S&P/ASX 200.
